The Biotech sector has had a very nice run over the past couple of years. Increased demand for new drugs has been very solid. However, development of new drugs is a difficult and slow process, and although Biotech growth remains solid, the blockbuster drugs cannot be duplicated every year. A new report from StockRing focuses in on just five stocks for clients to buy now. StockRing team is focused on growth in areas like new drugs manufacturing, which they addressed specifically in the new report. They feel that the industry move to faster drug development may be a huge boost to the sector and, more importantly, to sales. The five stocks currently rated at Buy from StockRing in the Biotech arena are: Dyax Corp. (NASDAQ: is DYAX), Esperion Therapeutics, Inc. (NASDAQ: ESPR), Targacept Inc. (NASDAQ: TRGT), Biogen Idec . (NASDAQ: BIIB) and China Biologic Products, Inc. (NASDAQ: CBPO).